rituximab

Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab
Hendrik Schulze-Koops, Klaus Krueger, Inka Vallbracht, Rebecca Hasseli, Alla Skapenko

Annals of the Rheumatic Diseases May 2021, 80 (5) e67; DOI: 10.1136/annrheumdis-2020-218075
Response to: ‘Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab’ by Schulze-Koops et al
Sara Monti, Carlomaurizio Montecucco

Annals of the Rheumatic Diseases May 2021, 80 (5) e68; DOI: 10.1136/annrheumdis-2020-218148
Response to: ‘Correspondence on ‘What comes after the lockdown? Clustering of ANCA-associated vasculitis: single-centre observation of a spatiotemporal pattern’’ by Hocevar et al
Philipp Gauckler, Erica L Bettac, Andreas Kronbichler

Annals of the Rheumatic Diseases Mar 2021, annrheumdis-2021-220324; DOI: 10.1136/annrheumdis-2021-220324
Response to: ‘Correspondence on ‘SARS-CoV-2 antibody response after COVID-19 in patients with rheumatic disease’’ by Shanoj et al
Kristin M D’Silva, Naomi Serling-Boyd, Tiffany Y-T Hsu, Jeffrey A Sparks, Zachary Scott Wallace

Annals of the Rheumatic Diseases Mar 2021, annrheumdis-2021-220166; DOI: 10.1136/annrheumdis-2021-220166
Correspondence on ‘SARS-CoV-2 antibody response after COVID-19 in patients with rheumatic disease’
Shanoj K C, Sakir Ahmed, Veena Shenoy, Aparna R Menon, Sanjo Saijan, Sageer AS Babu, Padmanabha Shenoy

Annals of the Rheumatic Diseases Mar 2021, annrheumdis-2021-220148; DOI: 10.1136/annrheumdis-2021-220148
Second COVID-19 infection in a patient with granulomatosis with polyangiitis on rituximab
Marcia A Friedman, Kevin L Winthrop

Annals of the Rheumatic Diseases Mar 2021, annrheumdis-2021-220088; DOI: 10.1136/annrheumdis-2021-220088
Severe COVID-19-associated pneumonia in 3 patients with systemic sclerosis treated with rituximab
Jérôme Avouac, Paolo Airó, Nicolas Carlier, Marco Matucci-Cerinic, Yannick Allanore

Annals of the Rheumatic Diseases Mar 2021, 80 (3) e37; DOI: 10.1136/annrheumdis-2020-217864
Response to: ‘Severe COVID-19 associated pneumonia in 3 patients with systemic sclerosis treated with rituximab’ by Avouac et al
Philippe Guilpain, Clément Le Bihan, Vincent Foulongne, Patrice Taourel, Nathalie Pansu, Alexandre Thibault Jacques Maria, Boris Jung, Romaric Larcher, Kada Klouche, Vincent Le Moing

Annals of the Rheumatic Diseases Mar 2021, 80 (3) e38; DOI: 10.1136/annrheumdis-2020-217955
Correspondence on ‘Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis’
Akshay Parikh, Phani Kumar Devarasetti, Liza Rajasekhar

Annals of the Rheumatic Diseases Feb 2021, annrheumdis-2020-219312; DOI: 10.1136/annrheumdis-2020-219312
Response to: ‘Correspondence on ‘Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis’’ by Parikh et al
Rona M Smith, Peter A Merkel, David Jayne

Annals of the Rheumatic Diseases Feb 2021, annrheumdis-2020-219329; DOI: 10.1136/annrheumdis-2020-219329

Main menu

rituximab

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

rituximab

Pages